TACR1 and breast cancer: 71 Besides mono-therapy, the introduction of a combination regimen consisting of NK1R antagonists (a receptor for neuropeptide Substance P) and COX-2 inhibitors demonstrated a significant reduction in breast cancer stemness capacity in TNBC cells thus improving the treatment sensitivity and lessening the risk of recurrence and relapse.6 These data strongly suggested that the introduction of myrrh natural medicine, via targeting the PTGS2, would provide a potent remedy in treating breast cancer patients.